Bio-Path Holdings, Inc. (NASDAQ:BPTH) is set to announce second quarter earning results on Friday 14th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BPTH to report 2Q20 loss of $ 0.96 per share.
For the full year, analysts anticipate loss of $ 3.77 per share bottom line.
Previous Quarter Performance
Bio-Path Holdings, Inc. recorded loss for the first quarter of $ 0.90 per share, from the revenue of . Wall street analysts are predicting, loss of $ 0.67 per share The bottom line results missed street analysts by $ 0.23 or 34.33 percent, at the same time, top line results analysts by $ 0.52 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of BPTH was $ 5.50, representing a 88.36 % increase from the 52 week low of $ 2.92 and a 58.99 % decrease over the 52 week high of $ 13.41.
The company has a market capital of $ 20.31 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BPTH” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
